Neurocrine's Phase 2 SAVITRI Study Meets Primary Endpoint For NBI-1065845 In Adults With MDD

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced positive results on Tuesday from its Phase 2 SAVITRI trial, which evaluated the effectiveness and safety of NBI-1065845 in adult patients with major depressive disorder or MDD.

The company confirmed that the trial met its primary and secondary goals, showing that the oral administration of NBI-1065845 once daily led to a significant improvement in the Montgomery Åsberg Depression Rating Scale total score compared to baseline at both Day 28 (primary) and Day 56 (secondary).

Neurocrine also noted that NBI-1065845 was generally well tolerated, with adverse events reported for both NBI-1065845 doses being similar to those observed in the placebo group.